<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Between 2000 and 2007, a demonstration pilot of biennial guaiac faecal occult blood test (GFOBT) screening was carried out in Scotland </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were defined as <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> diagnosed within 2 years (ie, a complete screening round) of a negative GFOBT </plain></SENT>
<SENT sid="2" pm="."><plain>The stage and outcome of the interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were compared with those arising contemporaneously in the non-screened Scottish population </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, the gender and site distributions of the interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were compared with those in the screen-detected group and the non-screened population </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> diagnosed in the screened population, interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> comprised 31.2% in the first round, 47.7% in the second, and 58.9% in the third, although this was due to a decline in the numbers of screen-detected <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> rather than an increase in interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>There were no consistent differences in the stage distribution of interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> from the non-screened population, and, in <z:hpo ids='HP_0000001'>all</z:hpo> three rounds, both overall and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival were significantly better for patients diagnosed with interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (p&lt;0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>The percentage of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> arising in women was significantly higher in the interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> group (50.2%) than in either the screen-detected group (35.3%, p&lt;0.001) or the non-screened group (40.6%, p&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, the proportion of both right-sided and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancers</z:e> was significantly higher in the interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> group than in either the screen-detected (p&lt;0.001) or non-screened (p&lt;0.004) groups </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Although GFOBT screening is associated with substantial interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> rates that increase with screening round, the absolute numbers do not </plain></SENT>
<SENT sid="9" pm="."><plain>Interval <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are associated with a better prognosis than <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> arising in a non-screened population, and GFOBT appears to preferentially detect <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in men and the left side of the colon at the expense of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in women and in the right colon and rectum </plain></SENT>
</text></document>